回盛生物股票讨论区

The company's high P/E ratio is backed by anticipated robust future growth, surpassing the broader market. Investors appear to dismiss the possibility of a substantial earnings decline, thus not justifying a lower P/E ratio. Hence, a significant drop in share price seems unlikely soon.